bioMérieux

bioMérieux is a family-owned diagnostic company dedicated to the research, development, manufacture, and sale of high-performance in vitro diagnostic solutions that enhance patient health and ensure consumer safety. As a global leader in in vitro diagnostics for 60 years, bioMérieux operates in 45 countries and serves over 160 countries through a broad network of distributors. The company’s headquarters is located in Marcy-l’Étoile, France, and it generates more than 93% of its revenue outside France.

bioMérieux is present on all continents, with 15 major production sites, 14 R&D centers, and numerous subsidiaries and offices. Nearly 13,000 employees contribute to bioMérieux’s public health mission while upholding the values of respect for humanity championed by the Mérieux family.

The company develops and offers the most appropriate diagnostic tests, considering medical needs (such as speed of results and precision medicine), laboratory parameters (including centralized and decentralized laboratories, as well as hospital and primary care settings), and technological advancements. As a world leader in microbiology, specializing in immunoassays and pioneering molecular syndromic approaches, bioMérieux is actively engaged in addressing significant public health challenges related to infectious diseases, including antimicrobial resistance, sepsis, and respiratory infections.

bioMérieux has been a major player in the diagnosis of infectious diseases since 1963, offering a wide and complementary range of technologies. Innovation is a key pillar of bioMérieux’s strategy, aiming to:

• Develop and produce diagnostic solutions that enable healthcare professionals to quickly and reliably identify diseases or the sources of contamination, providing crucial information for optimal patient management.
• Enhance the medical and predictive value of diagnostic test results.

Improve laboratory workflows and optimize overall operational performance.